Sagar Lonial

Sagar Lonial is affiliated with Emory University.[1]He specializes in oncology.[2]He is a member of Department of Hematology and Medical Oncology.[3]

Lonial is a professor and chair of the Department of Hematology and Medical Oncology and chief medical officer of the Winship Cancer Institute of Emory University in Atlanta, Georgia.[4]He serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium.[5]He noted the introduction of quad therapies – or the addition of one of the monoclonal antibodies – and the need to balance treatment with toxicities.[6]Board certified in hematology, oncology, and internal medicine, he has published over 200 scientific papers.[7]He serves on the editorial board of the Journal of Clinical Oncology and Leukemia and is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia.[7]His research has focused on combinations of novel agents for treatment of myeloma, as well as the development of new treatment strategies and targets for those with high-risk disease.[8]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Sagar Lonial on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Winship Cancer Institute of Emory University


  • 2


  • 806


  • 177


Recent events

FDA Approves Second Antibody for Myeloma

For the second time this month the FDA has approved a monoclonal antibody for treatment of relapsed or refractory multiple myeloma. The drug targets the plasma-cell surface protein SLAMF7 and, in a phase III randomized trial, led to a 4.5-month improvement in progression-free survival. The pivotal trial of elotuzumab involved 646 patients with myeloma that had relapsed or proven refractory to the most recent therapy. Lonial noted that elotuzumab received approval for use earlier in the time course of myeloma, as compared with daratumumab, which is approved for patients who have received three prior myeloma regimens.[91011]


Event Date

Alabama AD Bill Battle to take leave of absence for medical procedure

Battle will continue to direct the department while in daily communication with his staff. Battle will be undergoing a stem cell transplant under the supervision of Sagar Lonial, M.D., at The Bone Marrow and Stem Cell Transplant Center at the Winship Cancer Institute of Emory University in Atlanta, Ga. Battle is in stage one of the disease and it is not considered life-threatening. Dr. Lonial describes the disease as being in "a good partial remission," noting that the procedure is the standard "next step" of treatment. I am looking forward to getting this behind me and continuing my active lifestyle, as well as continuing to lead our Athletics Department.[121314]


Event Date


  1. 7
    Lonial Honored With Gray Family Chair in Cancer2019-01-30